About eTheRNA
eTheRNA immunotherapies is developing first in class mRNA immunotherapies for the treatment of cancer and infectious diseases. We employ messenger RNA to unleash and boost a patient’s immune response against a tumor or infectious agent. Research shows that this approach results in long lasting clinical remission in cancer patients and protective immunity against infections.
eTheRNA was established in January 2013 as a spin-off company from the ‘Vrije Universiteit Brussel’ (VUB), following the development of its TriMix mRNA technology.
What We Do
Immunotherapies
Contract Manufacturing
Newsroom
eTheRNA immunotherapies & Frame Therapeutics are awarded EUR 1.9 million Eurostars research grant for their novel cancer vaccine collaboration
Niel (Belgium) & Amsterdam (Netherlands)
A collaborative project between eTheRNA immunotherapies NV and Frame Therapeutics has been awarded a Eurostars grant totalling EUR 1.9 million for the development of a therapeutic vaccine for the treatment of kidney cancer. The Eurostars program aims to stimulate partnerships between European SMEs and start-ups to foster international collaboration and development of innovative technologies. eTheRNA immunotherapies and Frame Therapeutics began collaborating early in 2020, deploying mRNA technologies to develop novel cancer vaccines based on unique genetic mutations in patient tumours to stimulate a patient’s immune system against the tumour .
// eTheRNA
WE'D LIKE TO HEAR FROM YOU
Galileilaan 19, 2845 Niel, Belgium
Our Address
Our Mailbox
+32 3 369 17 40
Our Phone
© 2020 Etherna | Studio Hanswijk